239 related articles for article (PubMed ID: 33299233)
61. Novel site-specific PEGylated L-asparaginase.
Meneguetti GP; Santos JHPM; Obreque KMT; Barbosa CMV; Monteiro G; Farsky SHP; Marim de Oliveira A; Angeli CB; Palmisano G; Ventura SPM; Pessoa-Junior A; de Oliveira Rangel-Yagui C
PLoS One; 2019; 14(2):e0211951. PubMed ID: 30753228
[TBL] [Abstract][Full Text] [Related]
62. Investigating the gut microbial community and genes in children with differing levels of change in serum asparaginase activity during pegaspargase treatment for acute lymphoblastic leukemia.
Dunn KA; Connors J; Bielawski JP; Nearing JT; Langille MGI; Van Limbergen J; Fernandez CV; MacDonald T; Kulkarni K
Leuk Lymphoma; 2021 Apr; 62(4):927-936. PubMed ID: 33258724
[TBL] [Abstract][Full Text] [Related]
63. L-asparaginase activity and anti-L-asparaginase antibody as biomarkers in estimating PEG-asp-related anaphylaxis risk in childhood acute lymphoblastic leukemia patients.
Cui J; Jiang L; Xu B; Bai Y
Allergol Immunopathol (Madr); 2023; 51(3):28-35. PubMed ID: 37169557
[TBL] [Abstract][Full Text] [Related]
64. Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Salzer WL; Devidas M; Shuster JJ; Wang C; Chauvenet A; Asselin BL; Camitta BM; Kurtzberg J;
J Pediatr Hematol Oncol; 2007 Jun; 29(6):369-75. PubMed ID: 17551397
[TBL] [Abstract][Full Text] [Related]
65. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
Henriksen LT; Harila-Saari A; Ruud E; Abrahamsson J; Pruunsild K; Vaitkeviciene G; Jónsson ÓG; Schmiegelow K; Heyman M; Schrøder H; Albertsen BK;
Pediatr Blood Cancer; 2015 Mar; 62(3):427-33. PubMed ID: 25418987
[TBL] [Abstract][Full Text] [Related]
66. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia.
Soyer OU; Aytac S; Tuncer A; Cetin M; Yetgin S; Sekerel BE
J Allergy Clin Immunol; 2009 Apr; 123(4):895-9. PubMed ID: 19081614
[TBL] [Abstract][Full Text] [Related]
67. Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.
Heo YA; Syed YY; Keam SJ
Drugs; 2019 May; 79(7):767-777. PubMed ID: 31030380
[TBL] [Abstract][Full Text] [Related]
68. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future.
Avramis VI; Panosyan EH
Clin Pharmacokinet; 2005; 44(4):367-93. PubMed ID: 15828851
[TBL] [Abstract][Full Text] [Related]
69. Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia.
Ribera JM; Morgades M; Montesinos P; Martino R; Barba P; Soria B; Bermúdez A; Moreno MJ; González-Campos J; Vives S; Gil C; Abella E; Guàrdia R; Martínez-Carballeira D; Martínez-Sánchez P; Amigo ML; Mercadal S; Serrano A; López-Martínez A; Vall-Llovera F; Sánchez-Sánchez MJ; Peñarrubia MJ; Calbacho M; Méndez JA; Bergua J; Cladera A; Tormo M; García-Belmonte D; Feliu E; Ciudad J; Orfao A;
Leuk Lymphoma; 2018 Jul; 59(7):1634-1643. PubMed ID: 29165013
[TBL] [Abstract][Full Text] [Related]
70. Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol.
Raja RA; Schmiegelow K; Albertsen BK; Prunsild K; Zeller B; Vaitkeviciene G; Abrahamsson J; Heyman M; Taskinen M; Harila-Saari A; Kanerva J; Frandsen TL;
Br J Haematol; 2014 Apr; 165(1):126-33. PubMed ID: 24428625
[TBL] [Abstract][Full Text] [Related]
71. Treatment of severe hypertriglyceridemia associated with accidental pegylated asparaginase push in a child with relapsed acute lymphoblastic leukemia.
Malbora B; Avci Z; Ozbek N
Drug Chem Toxicol; 2012 Oct; 35(4):463-6. PubMed ID: 22149271
[TBL] [Abstract][Full Text] [Related]
72. Safety profile of a single pegylated asparaginase (PEG-ASP) dose in remission induction for acute lymphoblastic leukemia (ALL).
Helbig G; Armatys A; Boral K; Kopinska AJ; Wozniczka K; Dworaczek M; Chromik K; Koclega A; Panz-Klapuch M; Wysocka M; Janikowska A
Neoplasma; 2018 Nov; 65(6):993-997. PubMed ID: 29940768
[TBL] [Abstract][Full Text] [Related]
73. Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.
Gupta S; Wang C; Raetz EA; Schore R; Salzer WL; Larsen EC; Maloney KW; Mattano LA; Carroll WL; Winick NJ; Hunger SP; Loh ML; Devidas M
J Clin Oncol; 2020 Jun; 38(17):1897-1905. PubMed ID: 32275469
[TBL] [Abstract][Full Text] [Related]
74. Quality comparison of a state-of-the-art preparation of a recombinant L-asparaginase derived from Escherichia coli with an alternative asparaginase product.
Schnuchel A; Radcke C; Theobald L; Doeding S
PLoS One; 2023; 18(6):e0285948. PubMed ID: 37319282
[TBL] [Abstract][Full Text] [Related]
75. Polyoxazoline-Conjugated l-Asparaginase: An Antibody-Production-Free Therapeutic Agent for Acute Lymphoblastic Leukemia.
Yamada T; Ishimaru M; Shoji T; Tomiyasu H; Tochinai R; Taguchi K; Komatsu T
ACS Appl Bio Mater; 2023 Dec; 6(12):5789-5797. PubMed ID: 38047730
[TBL] [Abstract][Full Text] [Related]
76. [Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia].
Liu F; Wan Y; Chang L; Guo Y; Yang W; Wang S; Chen X; Liu T; Ruan M; Zhang L; Liu X; Zou Y; Chen Y; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Mar; 52(3):215-7. PubMed ID: 24824393
[TBL] [Abstract][Full Text] [Related]
77. Safety of mRNA-based COVID-19 vaccination in paediatric patients with a PEG-asparaginase allergy.
Broos N; Brigitha LJ; Schuurhof A; Röckmann-Helmbach H; Tissing WJE; Pieters R; van der Sluis IM; Stadermann MB
EJC Paediatr Oncol; 2023; 1():100002. PubMed ID: 38013843
[TBL] [Abstract][Full Text] [Related]
78. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
Vrooman LM; Stevenson KE; Supko JG; O'Brien J; Dahlberg SE; Asselin BL; Athale UH; Clavell LA; Kelly KM; Kutok JL; Laverdière C; Lipshultz SE; Michon B; Schorin M; Relling MV; Cohen HJ; Neuberg DS; Sallan SE; Silverman LB
J Clin Oncol; 2013 Mar; 31(9):1202-10. PubMed ID: 23358966
[TBL] [Abstract][Full Text] [Related]
79. Genetic predisposition to PEG-asparaginase hypersensitivity in children treated according to NOPHO ALL2008.
Højfeldt SG; Wolthers BO; Tulstrup M; Abrahamsson J; Gupta R; Harila-Saari A; Heyman M; Henriksen LT; Jónsson ÒG; Lähteenmäki PM; Lund B; Pruunsild K; Vaitkeviciene G; Schmiegelow K; Albertsen BK;
Br J Haematol; 2019 Feb; 184(3):405-417. PubMed ID: 30450575
[TBL] [Abstract][Full Text] [Related]
80. Analysis of Pre-existing IgG and IgM Antibodies against Polyethylene Glycol (PEG) in the General Population.
Yang Q; Jacobs TM; McCallen JD; Moore DT; Huckaby JT; Edelstein JN; Lai SK
Anal Chem; 2016 Dec; 88(23):11804-11812. PubMed ID: 27804292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
